<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36940001</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1724-6059</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of nephrology</Title><ISOAbbreviation>J Nephrol</ISOAbbreviation></Journal><ArticleTitle>Prevalence and clinical significance of ANCA positivity in lupus nephritis: a case series of 116 patients and literature review.</ArticleTitle><Pagination><StartPage>1059</StartPage><EndPage>1070</EndPage><MedlinePgn>1059-1070</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40620-023-01574-3</ELocationID><Abstract><AbstractText Label="UNLABELLED">The prevalence and clinical significance of anti-neutrophil cytoplasmic antibodies [ANCAs] in patients with lupus nephritis [LN] is not fully elucidated. Our aim was to determine whether LN patients with ANCA positivity had different clinicopathological features and outcomes compared to ANCA-negative patients.</AbstractText><AbstractText Label="METHODS">Among our LN patients we retrospectively selected those who underwent ANCA testing the day of the&#xa0;kidney biopsy and before the start of induction treatment. Clinical/histopathological features at kidney biopsy and renal outcome of ANCA-positive patients were compared with those of ANCA-negative subjects.</AbstractText><AbstractText Label="RESULTS">We included 116 Caucasian LN patients in the study; 16 patients [13.8%] were ANCA-positive. At kidney biopsy, ANCA-positive patients presented more frequently with an acute nephritic syndrome than ANCA-negative ones; the difference however&#xa0;does not reach statistical significance [44 vs. 25%, p&#x2009;=&#x2009;0.13]. At histological evaluation, proliferative classes [100% vs 73%; p&#x2009;=&#x2009;0.02], class IV [68.8% vs 33%; p&#x2009;&lt;&#x2009;0.01] and necrotizing tuft lesions [27 vs 7%, p&#x2009;=&#x2009;0.04] were more frequent, and the activity index was higher [10 vs 7; p&#x2009;=&#x2009;0.03] in ANCA-positive than in ANCA-negative patients. Despite worse histological features, after a 10-year observation period, there were no significant differences in the number of patients with chronic kidney function impairment (defined as eGFR&#xa0;&lt;&#xa0;60&#xa0;mL/min&#xa0;per 1.73&#xa0;m<sup>2</sup>) between the ANCA-positive and negative groups [24.2 vs 26.6%, p&#x2009;=&#x2009;0.9]. This could be the result of the more aggressive therapy, with rituximab plus cyclophosphamide, that ANCA-positive patients received more frequently than ANCA-negative ones [25 vs. 1.3%, p&#x2009;&lt;&#x2009;0.01].</AbstractText><AbstractText Label="CONCLUSIONS">ANCA-positive LN patients frequently have histological markers of severe activity (proliferative classes and high activity index) that require timely diagnosis and aggressive therapy to limit the development of irreversible chronic kidney damage.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s) under exclusive licence to Italian Society of Nephrology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lacetera</LastName><ForeName>Rosanna</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Nephrology and Dialysis Unit, IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089, Rozzano, Milan, Italy. r.lacetera@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calatroni</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Nephrology and Dialysis Unit, IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089, Rozzano, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072, Pieve Emanuele, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089, Rozzano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roggero</LastName><ForeName>Letizia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Nephrology and Dialysis Unit, IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089, Rozzano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Radice</LastName><ForeName>Antonella</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Microbiology Institute, ASST [Azienda Socio Sanitaria Territoriale] Santi Paolo e Carlo, 20142, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pozzi</LastName><ForeName>Maria Rosa</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Rheumatology Unit, ASST-Monza, Ospedale San Gerardo, 20900, Monza, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reggiani</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Nephrology and Dialysis Unit, IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089, Rozzano, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072, Pieve Emanuele, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089, Rozzano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sciascia</LastName><ForeName>Savino</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center of Research of Immunopathology and Rare Diseases-CMID, Coordinating Center of the Network for Rare Diseases of Piedmont and Aosta Valley, and Nephrology and Dialysis Division [ERKnet Member], Department of Clinical and Biological Sciences of the University of Turin, San Giovanni Bosco Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trezzi</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Medicine and Surgery, University of Milano Bicocca and Nephrology and Dialysis Unit, ASST-Monza, San Gerardo Hospital, Milan, Monza, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roccatello</LastName><ForeName>Dario</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Center of Research of Immunopathology and Rare Diseases-CMID, Coordinating Center of the Network for Rare Diseases of Piedmont and Aosta Valley, and Nephrology and Dialysis Division [ERKnet Member], Department of Clinical and Biological Sciences of the University of Turin, San Giovanni Bosco Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minetti</LastName><ForeName>Enrico</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Nephrology, Niguarda Ca' Granda Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Moroni</LastName><ForeName>Gabriella</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072, Pieve Emanuele, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089, Rozzano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Sinico</LastName><ForeName>Renato Alberto</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Medicine and Surgery, University of Milano Bicocca and Nephrology and Dialysis Unit, ASST-Monza, San Gerardo Hospital, Milan, Monza, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>J Nephrol</MedlineTA><NlmUniqueID>9012268</NlmUniqueID><ISSNLinking>1121-8428</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019268">Antibodies, Antineutrophil Cytoplasmic</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019268" MajorTopicYN="N">Antibodies, Antineutrophil Cytoplasmic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000092522" MajorTopicYN="N">Clinical Relevance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anti-neutrophil cytoplasmic antibody</Keyword><Keyword MajorTopicYN="N">Kidney biopsy, Long-term kidney survival</Keyword><Keyword MajorTopicYN="N">Lupus nephritis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>20</Day><Hour>12</Hour><Minute>24</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36940001</ArticleId><ArticleId IdType="doi">10.1007/s40620-023-01574-3</ArticleId><ArticleId IdType="pii">10.1007/s40620-023-01574-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Crisp&#xed;n JC, Liossis SN, Kis-Toth K, et al. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med. 2010 Feb;16[2]:47&#x2013;57. https://doi.org/10.1016/j.molmed.2009.12.005 . Epub 2010 Feb 4. PMID: 20138006; PMCID: PMC2823952.</Citation></Reference><Reference><Citation>Parikh SV, Almaani S, Brodsky S, Rovin BH (2020) Update on Lupus Nephritis: Core Curriculum 2020. Am J Kidney Dis 76(2):265&#x2013;281. https://doi.org/10.1053/j.ajkd.2019.10.017 . (Epub 2020 Mar 24 PMID: 32220510)</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2019.10.017</ArticleId><ArticleId IdType="pubmed">32220510</ArticleId></ArticleIdList></Reference><Reference><Citation>Pons-Estel GJ, Alarc&#xf3;n GS, Scofield L, Reinlib L, Cooper GS. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum. 2010 Feb;39[4]:257&#x2013;68. doi: https://doi.org/10.1016/j.semarthrit.2008.10.007 . Epub 2009 Jan 10. PMID: 19136143; PMCID: PMC2813992.</Citation></Reference><Reference><Citation>Chen YE, Korbet SM, Katz RS, Schwartz MM, Lewis EJ; Collaborative Study Group. Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol. 2008 Jan;3[1]:46&#x2013;53. doi: https://doi.org/10.2215/CJN.03280807 . Epub 2007 Nov 14. PMID: 18003764; PMCID: PMC2390978.</Citation></Reference><Reference><Citation>Tektonidou MG, Dasgupta A, Ward MM (2016) Risk of end-stage renal disease in patients with lupus nephritis, 1971&#x2013;2015: a systematic review and bayesian meta-analysis. Arthritis Rheumatol 68(6):1432&#x2013;1441. https://doi.org/10.1002/art.39594.PMID:26815601;PMCID:PMC5071782</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39594.PMID:26815601;PMCID:PMC5071782</ArticleId><ArticleId IdType="pubmed">26815601</ArticleId><ArticleId IdType="pmc">5071782</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilliam BE, Ombrello AK, Burlingame RW, Pepmueller PH, Moore TL (2012) Measurement of autoantibodies in pediatric-onset systemic lupus erythematosus and their relationship with disease-associated manifestations. Semin Arthritis Rheum 41(6):840&#x2013;848. https://doi.org/10.1016/j.semarthrit.2011.09.009 . (Epub 2011 Dec 15 PMID: 22177108)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2011.09.009</ArticleId><ArticleId IdType="pubmed">22177108</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi S, Xue J, Li F et al (2016) Correlation of Serum Soluble Interleukin-7 Receptor and Anti-C1q Antibody in Patients with Systemic Lupus Erythematosus. Autoimmune Diseases 2016:8252605. https://doi.org/10.1155/2016/8252605.PMID:27069677;PMCID:PMC4812203</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/8252605.PMID:27069677;PMCID:PMC4812203</ArticleId><ArticleId IdType="pubmed">27069677</ArticleId><ArticleId IdType="pmc">4812203</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Hussain T, Hussein MH, Conca W, Al Mana H, Akhtar M (2017) Pathophysiology of ANCA-associated Vasculitis. Adv Anat Pathol 24(4):226&#x2013;234. https://doi.org/10.1097/PAP.0000000000000154 . (PMID: 28537941)</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PAP.0000000000000154</ArticleId><ArticleId IdType="pubmed">28537941</ArticleId></ArticleIdList></Reference><Reference><Citation>Csernok, E., Holle, J., Hellmich, et al. Evaluation of capture ELISA for detection of antineutrophil cytoplasmic antibodies directed against proteinase 3 in Wegener's granulomatosis: first results from a multicentre study. Rheumatology, 2004, 43[2],174&#x2013;180.</Citation></Reference><Reference><Citation>Merkel PA, Polisson RP, Chang Y, Skates SJ, Niles JL (1997) Prevalence of antineutrophil cytoplasmic antibodies in a large inception cohort of patients with connective tissue disease. Ann Intern Med 126(11):866&#x2013;873. https://doi.org/10.7326/0003-4819-126-11-199706010-00003 . (PMID: 9163287)</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-126-11-199706010-00003</ArticleId><ArticleId IdType="pubmed">9163287</ArticleId></ArticleIdList></Reference><Reference><Citation>Su F, Xiao W, Yang P, Chen Q, Sun X, Li T (2017) Anti-neutrophil cytoplasmic antibodies in new-onset systemic lupus erythematosus. An Bras Dermatol 92(4):466&#x2013;469. https://doi.org/10.1590/abd1806-4841.20175476</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/abd1806-4841.20175476</ArticleId><ArticleId IdType="pubmed">28954092</ArticleId><ArticleId IdType="pmc">5595590</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradhan VD, Badakere SS, Bichile LS, Almeida AF (2004) Anti-neutrophil cytoplasmic antibodies [ANCA] in systemic lupus erythematosus: prevalence, clinical associations and correlation with other autoantibodies. J Assoc Physicians India 52:533&#x2013;537 (PMID: 15645975)</Citation><ArticleIdList><ArticleId IdType="pubmed">15645975</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan HF, Fang XH, Wu, GC.&#xa0;et al.&#xa0;Anti-neutrophil Cytoplasmic Antibodies in New-onset Systemic Lupus Erythematosus and Lupus Nephritis.&#xa0;Inflammation, 2008, 31,&#xa0;260. https://doi.org/10.1007/s10753-008-9073-3</Citation></Reference><Reference><Citation>Wang Y, Huang X, Cai J et al. Clinicopathologic Characteristics and Outcomes of Lupus Nephritis With Antineutrophil Cytoplasmic Antibody: A Retrospective Study. Medicine [Baltimore]. 2016 Jan;95[4]: e2580. doi: https://doi.org/10.1097/MD.0000000000002580 . PMID: 26825903; PMCID: PMC5291573.</Citation></Reference><Reference><Citation>Li Cui, Zhou ML, Liang DD, et al. Treatment and clinicopathological characteristics of lupus nephritis with anti-neutrophil cytoplasmic antibody positivity: a case-control study.&#xa0;BMJ Open. 2017;7[7]: e015668. Published 2017 Jul 28. doi: https://doi.org/10.1136/bmjopen-2016-015668</Citation></Reference><Reference><Citation>Pyo JY, Jung SM, Song JJ, Park YB, Lee SW (2019) ANCA positivity at the time of renal biopsy is associated with chronicity index of lupus nephritis. Rheumatol Int 39(5):879&#x2013;884. https://doi.org/10.1007/s00296-019-04263-2 . (Epub 2019 Feb 26 PMID: 30806732)</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-019-04263-2</ArticleId><ArticleId IdType="pubmed">30806732</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner-Stokes T, Wilson HR, Morreale M et al (2017) Positive antineutrophil c ytoplasmic antibody serology in patients with lupus nephritis is associated with distinct histopathologic features on renal biopsy. Kidney Int 92(5):1223&#x2013;1231. https://doi.org/10.1016/j.kint.2017.04.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2017.04.029</ArticleId><ArticleId IdType="pubmed">28750930</ArticleId><ArticleId IdType="pmc">5652376</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Orbai AM, Alarc&#xf3;n GS et al (2012) Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64(8):2677&#x2013;2686. https://doi.org/10.1002/art.34473.PMID:22553077;PMCID:PMC3409311</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34473.PMID:22553077;PMCID:PMC3409311</ArticleId><ArticleId IdType="pubmed">22553077</ArticleId><ArticleId IdType="pmc">3409311</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019 Sep;71[9]:1400&#x2013;1412. doi: https://doi.org/10.1002/art.40930 . Epub 2019 Aug 6. PMID: 31385462; PMCID: PMC6827566.</Citation></Reference><Reference><Citation>Sinico RA, Radice A. Antineutrophil cytoplasmic antibodies [ANCA] testing: detection methods and clinical application. Clin Exp Rheumatol. 2014 May-Jun;32[3 Suppl 82]: S112&#x2013;7. Epub 2014 May 15. PMID: 24854381.</Citation></Reference><Reference><Citation>Bossuyt X, Cohen Tervaert JW et al (2017) Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nat Rev Rheumatol 13(11):683&#x2013;692. https://doi.org/10.1038/nrrheum.2017.140</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2017.140</ArticleId><ArticleId IdType="pubmed">28905856</ArticleId></ArticleIdList></Reference><Reference><Citation>Moroni G, Vercelloni PG, Quaglini S et al. A. Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis. Ann Rheum Dis. 2018 Sep;77[9]:1318&#x2013;1325. doi: https://doi.org/10.1136/annrheumdis-2017-212732 . Epub 2018 May 5. PMID: 29730634.</Citation></Reference><Reference><Citation>Bajema IM, Wilhelmus S, Alpers CE et al (2018) Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int 93:789</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2017.11.023</ArticleId><ArticleId IdType="pubmed">29459092</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin HA, Muenz LR, Joyce KM et al. Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med. 1983; 75: 382&#x2013;91.</Citation></Reference><Reference><Citation>Hill GS, Delahousse M, Nochy D et al (2000) A new morphologic index for the evaluation of renal biopsies in lupus nephritis. Kidney Int 58:1160&#x2013;1173</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1523-1755.2000.00272.x</ArticleId><ArticleId IdType="pubmed">10972679</ArticleId></ArticleIdList></Reference><Reference><Citation>Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009 May 5;150(9):604&#x2013;12. doi: https://doi.org/10.7326/0003-4819-150-9-200905050-00006 . Erratum in: Ann Intern Med. 2011 Sep 20;155(6):408. PMID: 19414839; PMCID: PMC2763564.</Citation></Reference><Reference><Citation>Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, De Zeeuw D, Hostetter TH, Lameire N, Eknoyan G (2005) Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 67(6):2089&#x2013;2100. https://doi.org/10.1111/j.1523-1755.2005.00365.x . (PMID: 15882252)</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1523-1755.2005.00365.x</ArticleId><ArticleId IdType="pubmed">15882252</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Shang J, Xiao J, Zhao Z (2020) Clinicopathologic characteristics and outcomes of lupus nephritis with positive antineutrophil cytoplasmic antibody. Ren Fail 42(1):244&#x2013;254. https://doi.org/10.1080/0886022X.2020.1735416</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/0886022X.2020.1735416</ArticleId><ArticleId IdType="pubmed">32228220</ArticleId><ArticleId IdType="pmc">7067160</ArticleId></ArticleIdList></Reference><Reference><Citation>Amann K (2017) Do ANCAs make the difference in lupus nephritis? Kidney Int 92(5):1048&#x2013;1050. https://doi.org/10.1016/j.kint.2017.07.011 . (PMID: 29055427)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2017.07.011</ArticleId><ArticleId IdType="pubmed">29055427</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahajan A, Amelio J, Gairy K, Kaur G, Levy RA, Roth D, Bass D. Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression. Lupus. 2020 Aug;29(9):1011&#x2013;1020. doi: https://doi.org/10.1177/0961203320932219 . Epub 2020 Jun 22. PMID: 32571142; PMCID: PMC7425376..</Citation></Reference><Reference><Citation>Wang H, Ren Y, Chang J et al (2018) A systematic review and meta-analysis of prevalence of biopsy-proven lupus nephritis. Arch Rheumatol 33:17&#x2013;25</Citation><ArticleIdList><ArticleId IdType="doi">10.5606/ArchRheumatol.2017.6127</ArticleId><ArticleId IdType="pubmed">29900975</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Zhao Z, Hu X. Effect of Rituximab on Serum Levels of anti-C1q and Antineutrophil Cytoplasmic Autoantibodies in Refractory Severe Lupus nephritis Cell Biochem Biophys. 2015; 72(1):197&#x2013;201. doi: https://doi.org/10.1007/s12013-014-0437-z .</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>